NuSirt Sciences

NuSirt Sciences is a biopharmaceutical company developing sirtuin pathway activators to treat cardiometabolic diseases associated with aging and overnutrition, including metabolic-associated fatty liver disease, obesity, type 2 diabetes, and hypertension. The company's lead candidate is TRIPLN®, a combination of L-leucine, metformin, and sildenafil currently in phase 2 clinical trials, and it also produces LEUSIX®, a dietary supplement for cardiometabolic health and weight management.